@LiamCristiano @dangermanisreal high dose topical testosterone barely causes shutdown DHT in lower doses most definit...
Social commentary suggests high‑dose topical testosterone produces minimal shutdown of DHT, while lower doses may increase endogenous HPG (hypothalamic–pituitary–gonadal) activity. This thread is physiologic observation, not a corporate or product disclosure.
Linked assets
This thesis references the biological marker DHT (dihydrotestosterone). No company tickers, ETFs, products, or investable securities are identified.
Biological marker: DHT (dihydrotestosterone). The discussion concerns how topical testosterone dosing affects DHT levels and HPG-axis hormones.
Social commentary claims that high‑dose topical testosterone only minimally suppresses DHT, whereas lower topical doses may increase endogenous HPG activity. Sources reference modest, dose‑dependent reductions in FSH and LH. No company, product, or tradable asset is identified; this is a physiological observation rather than an investment signal.
Source proof
Source proof: Supported source proof | 2 extracted claims | 1 directional asset | 1 supporting author | headline-like title review
Underlying sources are social-media posts and informal commentary describing dose-dependent effects of topical testosterone on FSH, LH, and DHT, plus anecdotal recommendations and unrelated health tips. None include firm names, drugs, pricing, regulatory events, or trading catalysts.
Commentary about an unspecified substance reducing FSH and LH modestly, in a dose-dependent manner. No company, drug, catalyst, or tradable asset is identified.
Discussion about physiological effects of topical testosterone and DHT on HPG axis activity; no explicit market, company, product, or investable asset referenced.
The source only states that the user has heard “tons of strong reviews” about @JK99928789839, with no identifiable company/ticker, product, catalyst, timeframe, or tradable implication.
Non-financial social post about skincare/sun exposure increasing skin sensitivity; no market, company, or asset implications.
Post claims that for people with candida, temporarily cutting complex carbohydrates is key to getting rid of it. No mention of markets, companies, products, or investable assets.
The content is a brief product recommendation (Miyasi brand on Amazon) with no market, macro, earnings, regulatory, or industry details. It does not specify product category, volume, demand trends, pricing, or competitive dynamics, so it is not actionable for investment/trading purposes beyond a very general Amazon marketplace context.
The provided text is a personal question about “form and dosage” with no market, macro, sector, or company information. It is not actionable for investment research and contains no tradable signals or tickers.
Discussion of supplement/compound 9-me-bc pharmacology (half-life, MAO inhibition, potential toxic beta-carboline metabolites). No companies, products, catalysts, pricing, or market/financial implications provided.
Supporting authors
Content derives from one author thread and related social posts; attribution is to the original handles quoted in the thesis. No institutional research or peer‑reviewed studies are provided in these sources.
Unlock full thesis monitoring
This material is physiological and conversational in nature and does not constitute an investable thesis. Use it only as background on hormone-response hypotheses; consult clinical literature for definitive mechanisms or therapeutic implications.